Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29086618 | 0.91 | OPRM1 (0.41) | DNM1OPRM1TSHRLMNA | |
| SCHEMBL5107760 | 0.84 | — | — | |
| SCHEMBL5100724 | 0.81 | ALDH1A1 (0.33) | DNM1OPRM1ALDH1A1TDP1TSHR | |
| SCHEMBL7468783 | 0.81 | TSHR (0.40) | TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL28956396 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL11636019 | 0.76 | — | — | |
| SCHEMBL21722647 | 0.75 | DNM1 (0.31) | DNM1OPRM1 | |
| SCHEMBL15013921 | 0.75 | HSD17B10 (0.37) | TDP1 | |
| SCHEMBL387200 | 0.74 | — | — | |
| SCHEMBL8074240 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20060019831-A1 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-26 | — | — | US | disclosed |
| EP-1556346-A1 | 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037787-A1 | 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019831-A1 | 1-phenylpyrrolidine-2-one-3-carboxamides | RXFP1, REN, NPY1R | DNM1 1324/4885OPRM1 1640/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.